TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37640025
Drug: anti-PD-1 antibody
Normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1 antibody plus anti-vascular endothelial growth factor receptor 2 inhibitors and eribulin
Study: 37640455
Drug: Medical grade
Normalized name: Skarcade Medical Grade Silicone Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical grade honey (L-Mesitran, treatment)
Study: 37640625
Drug: Anakinra 100mg
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 100mg daily subcutaneous dose during hospitalization
Study: 37640809
Drug: Enteral L-citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral L-citrulline supplementation (100 mg/kg/day) for 7 days
Study: 37640809
Drug: Enteral L-citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral L-citrulline supplementation (200 mg/kg/day) for 7 days
Study: 37640809
Drug: Enteral L-citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral L-citrulline supplementation (300 mg/kg/day) for 7 days
Study: 37640860
Drug: Bivalent variant
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent variant vaccines
Study: 37640860
Drug: Monovalent variant
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent variant vaccines
Study: 37640889
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of maternal age, vaginal bleeding, CRL, and hCG
Study: 37641136
Drug: FX06 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FX06 (400 mg/d, for 5 days)
Study: 37641555
Drug: Aneurysm treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aneurysm treatment <6 h after rupture
Study: 37641555
Drug: Aneurysm treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aneurysm treatment 6-24 h after rupture
Study: 37641586
Drug: Active Intradermal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Intradermal Acupuncture combined with SSRIs (AIA)
Study: 37641586
Drug: Sham Intradermal
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Intradermal Acupuncture combined with SSRIs (SIA)
Study: 37641586
Drug: Selective Serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Serotonin Reuptake Inhibitors (SSRIs)-only group
Study: 37642032
Drug: Post-PCI fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-PCI fractional flow reserve measurement after drug-eluting stent implantation; identified adverse clinical characteristics include age ≥65 years, diabetes, chronic kidney disease, left ventricular ejection fraction <50%; identified adverse vessel characteristics include post-PCI fractional flow reserve ≤0.80 and total stent length ≥54 mm.
Study: 37643290
Drug: Combination HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination HIV prevention strategies implemented at the community level
Study: 37643382
Drug: Atezolizumab (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1,200 mg once every 3 weeks) combined with bevacizumab and six cycles of chemotherapy doublet
Study: 37643382
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with bevacizumab and six cycles of chemotherapy doublet
Study: 37643392
Drug: Weekly phone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly phone counseling sessions with bidirectional text messages
Study: 37643392
Drug: Weekly phone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly phone counseling sessions with unidirectional text messages
Study: 37643520
Drug: LDL-C Q1
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C Q1 (≤1.76 mmol/L)
Study: 37643520
Drug: LDL-C Q2
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C Q2 (1.77-2.36 mmol/L)
Study: 37643520
Drug: LDL-C Q3
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C Q3 (2.37-2.93 mmol/L)
Study: 37643520
Drug: LDL-C Q4
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C Q4 (>2.93 mmol/L)
Study: 37643848
Drug: Volatile organic
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volatile organic compounds (VOCs) in exhaled air analyzed by gas chromatography time-of-flight mass spectrometry
Study: 37643847
Drug: IPL combined
Normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPL combined with 3% diquafosol ophthalmic solution (IPL+)
Study: 37643847
Drug: DQS (3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DQS (3% diquafosol ophthalmic solution eye-drops) (active control group)
Study: 37643887
Drug: 4,500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4,500 mg of IV semorinemab every 4 weeks for 48 or 60 weeks
Study: 37644354
Drug: BRIGHT (brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRIGHT (brief cognitive behavioral therapy)
Study: 37644869
Drug: Calcipotriol/betamethasone in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol/betamethasone in combination with NBUVB
Study: 37644980
Drug: Intradialytic regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic regional cerebral oxygenation (rSO2) monitoring during the first 72 hours of continuous kidney replacement therapy or throughout each session of intermittent hemodialysis.
Study: 37645440
Drug: Clinical pharmacist-led
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacist-led intervention for drug-related problems
Study: 37645622
Drug: Tusamitamab ravtansine
Normalized name: Tusamitamab ravtansine
DrugBank: Tusamitamab ravtansine (DB17448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tusamitamab ravtansine at 170 mg/m²
Study: 37645622
Drug: Tusamitamab ravtansine
Normalized name: Tusamitamab ravtansine
DrugBank: Tusamitamab ravtansine (DB17448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tusamitamab ravtansine at 100 mg/m²
Study: 37645940
Drug: Remote telehealth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote telehealth Transitional Pain Service (TPS) with opioid-tapering CBT protocol
Study: 37646148
Drug: rurioctocog alfa
Normalized name: Rurioctocog alfa
Approvals — FDA: no, EMA: no, PMDA: no
Description: rurioctocog alfa pegol (on-demand treatment)
Study: 37646214
Drug: Transcatheter edge-to-edge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter edge-to-edge repair with the MitraClip device plus maximally tolerated guideline-directed medical therapy (GDMT)
Study: 37646657
Drug: Melflufen 30
Normalized name: Melflufen
DrugBank: Melphalan flufenamide (DB16627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melflufen 30 mg plus dexamethasone and daratumumab
Study: 37646657
Drug: Melflufen 40
Normalized name: Melflufen
DrugBank: Melphalan flufenamide (DB16627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melflufen 40 mg plus dexamethasone and daratumumab
Study: 37646659
Drug: Loncastuximab tesirine
Normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loncastuximab tesirine (0.15 mg/kg for 2 cycles; 0.075 mg/kg for subsequent cycles)
Study: 37646670
Drug: Lisocabtagene maraleucel
Normalized name: Lisocabtagene Maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisocabtagene maraleucel (liso-cel), an autologous, CD19-directed, 4-1BB CAR T-cell product administered at a total target dose of 100×10⁶ CAR+ T cells.
Study: 37646678
Drug: Two-antibody method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-antibody method (EBNA1-IgA and VCA-IgA)
Study: 37646678
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of P85-Ab and two-antibody method
Study: 37646702
Drug: Mezigdomide plus
Normalized name: Mezigdomide
DrugBank: Mezigdomide (DB17584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezigdomide plus dexamethasone (1.0 mg once daily for 21 days, followed by 7 days off, in each 28-day cycle)
Study: 37646988
Drug: 8000 IU
Normalized name: Ergocalciferol 8000 IU/1 ML Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8000 IU daily with a loading dose of 50,000 IU
Study: 37646988
Drug: Standard-of-care control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care control dose (600 IU daily)
Study: 37646988
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 50,000 IU
Study: 37647317
Drug: VRVF device
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRVF device (self-administered remote visual field monitoring)
Study: 37647601
Drug: Vibecotamab (XmAb14045)
Normalized name: Vibecotamab
DrugBank: Vibecotamab (DB18872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibecotamab (XmAb14045) at a target dose of 0.75 μg/kg or higher (n=87)
Study: 37647728
Drug: TQB2450 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 plus anlotinib 10 mg
Study: 37647728
Drug: TQB2450 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 plus anlotinib 12 mg
Study: 37648383
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g azithromycin
Study: 37648393
Drug: Azithromycin administered
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin administered concurrently with the first and third doses of pentavalent vaccines (Penta-1/3)
Study: 37648417
Drug: Short oral/two-step
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short oral/two-step consent (SOC)
Study: 37648579
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg once daily in addition to standard of care therapy
Study: 37649617
Drug: Moderna mRNA-1273
Normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderna mRNA-1273 vaccine
Study: 37650231
Drug: Novel therapeutics
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel therapeutics for the treatment of early COVID-19, specific interventions not detailed.
Study: 37650230
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies (mAbs)
Study: 37650234
Drug: Investigational agents
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational agents (specific agents not detailed)
Study: 37650235
Drug: Antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral treatment in outpatient trials
Study: 37650754
Drug: Microablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microablative fractional CO laser treatment
Study: 37650759
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever vaccine (17DD)
Study: 37650808
Drug: Best-practices Treatment
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best-practices Treatment as Usual (TAU)
Study: 37651119
Drug: Niacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin (100 mg)
Study: 37651373
Drug: High-dose TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose TXA (20 mg/kg loading dose followed by 5 mg/kg/h continuous infusion)
Study: 37651373
Drug: Low-dose TXA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose TXA (20 mg/kg loading dose followed by continuous infusion of normal saline)
Study: 37651654
Drug: Interval-compressed chemotherapy
Normalized name: Ulva compressa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval-compressed chemotherapy
Study: 37651655
Drug: Tisotumab vedotin
Normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tisotumab vedotin (TV) + Carboplatin (1L treatment); TV 2 mg/kg + Carboplatin AUC 5 on day 1 every 3 weeks
Study: 37651655
Drug: Tisotumab vedotin
Normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tisotumab vedotin (TV) + Pembrolizumab (1L treatment); TV 2 mg/kg + Pembrolizumab 200 mg on day 1 every 3 weeks
Study: 37651655
Drug: Tisotumab vedotin
Normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tisotumab vedotin (TV) + Pembrolizumab (2L/3L treatment); TV 2 mg/kg + Pembrolizumab 200 mg on day 1 every 3 weeks
Study: 37651655
Drug: Tisotumab vedotin
Normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tisotumab vedotin (TV) + Bevacizumab; TV 2 mg/kg + Bevacizumab 15 mg/kg on day 1 every 3 weeks
Study: 37651676
Drug: Nivolumab (NIVO)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (NIVO) monotherapy
Study: 37651844
Drug: Oral fumarate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fumarate therapy
Study: 37652094
Drug: Local budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Local budesonide therapy (budesonide and physiological saline nasal irrigations administered via three syringes of 20 ml in each nasal cavity in the morning and evening for 30 days)
Study: 37652356
Drug: Vaccine Acceptance
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine Acceptance Intervention (VAI) training
Study: 37652554
Drug: Ustekinumab (UST)
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab (UST) 6 mg/kg intravenous at week 0 followed by 90 mg subcutaneous every 8 weeks from week 8 to week 24
Study: 37652940
Drug: HMO-Concentrate administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMO-Concentrate administered orally for 7 days
Study: 37653140
Drug: Bispecific antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bispecific antibodies targeting GPRC5D
Study: 37653215
Drug: GLP-1RA +
Normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GLP-1RA + Met (liraglutide, 1.2-1.8 mg/day + Met 1500 mg/day)
Study: 37653215
Drug: CPA/EE +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPA/EE + Met (2 mg/day CPA and 35 μg EE + Met 1500 mg/day)
Study: 37653218
Drug: Prophylactic low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prophylactic low-dose hydrocortisone (HC)
Study: 37653525
Drug: High-Intensity Laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Laser Therapy (HILT) and stretching exercises
Study: 37653525
Drug: Sham High-Intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham High-Intensity Laser Therapy (sham HILT) and stretching exercises
Study: 37653536
Drug: Mother-Child Emotional
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mother-Child Emotional Preparation (MCEP)
Study: 37653768
Drug: PP6M (700/1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: PP6M (700/1000 mg eq.)
Study: 37653768
Drug: PP3M (350/525
Approvals — FDA: no, EMA: no, PMDA: no
Description: PP3M (350/525 mg eq.)
Study: 37654659
Drug: Non-invasive physical
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive physical plasma (NIPP) treatment
Study: 37654668
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody treatment
Study: 37654668
Drug: Corticosteroids therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids therapy for mild/severe cases
Study: 37654668
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with monoclonal Ab
Study: 37654895
Drug: Acetaminophen (APAP)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP) + anti-PD-1 treatment (sintilimab)
Study: 37654895
Drug: Anti-PD-1 treatment
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 treatment (sintilimab) alone
Study: 37654895
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of APAP and anti-PD-1 treatment
Study: 37655106
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (13 patients)
Study: 37655106
Drug: Neoadjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant immunotherapy (26 patients)
Study: 37655205
Drug: selpercatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: selpercatinib treatment
Study: 37655258
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention in addition to optimal medical therapy
Study: 37656413
Drug: Compound Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Danshen Dripping Pills (CDDP) - 20 tablets before pPCI and 10 tablets 3 times daily after pPCI
Study: 37656413
Drug: Compound Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Danshen Dripping Pills (CDDP)
Study: 37656441
Drug: Anti-IL6-directed therapy
Normalized name: DIRECT BLUE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IL6-directed therapy (siltuximab or tocilizumab)
Study: 37656948
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by surgery (NACT-S), n = 314
Study: 37657279
Drug: Usual Community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Community Care (CC)
Study: 37657460
Drug: TTFields therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFields therapy with standard systemic therapy (investigator's choice of immune checkpoint inhibitor or docetaxel)
Study: 37856212
Drug: Standard systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systemic therapy alone
Study: 37657460
Drug: TTFields therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFields therapy with standard systemic therapy
Study: 37657460
Drug: TTFields therapy-related
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFields therapy-related adverse events
Study: 37657463
Drug: Adenoviral vectors
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenoviral vectors expressing HSV1-TK and Flt3L, administered via injections into the tumor bed after maximal safe resection, with six escalating doses starting from 1×10 (exact dosage not specified).
Study: 37657463
Drug: Adenoviral vectors
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenoviral vectors expressing HSV1-TK and Flt3L (combined treatment).
Study: 37657522
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 0.125 M L-glutamic acid at 1.65 mL/kg/h for 150 min before reperfusion
Study: 37657522
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 0.125 M L-glutamic acid
Study: 37657525
Drug: TwHF monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TwHF monotherapy
Study: 37657523
Drug: Oligofructose 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose 8 g/d (plus 2 g/d maltodextrin)
Study: 37657523
Drug: Oligofructose 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose 8 g/d plus 2'fucosyllactose (2 g/d)
Study: 37657523
Drug: 2'fucosyllactose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2'fucosyllactose 2 g/d (plus 8 g/d maltodextrin)
Study: 37657523
Drug: Maltodextrin 10
Normalized name: maltodextrin 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin 10 g/d
Study: 37657768
Drug: Atrasentan (endothelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan (endothelin receptor antagonist)
Study: 37657939
Drug: Neflamapimod 40
Normalized name: Neflamapimod
DrugBank: Neflamapimod (DB07138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neflamapimod 40 mg three times daily (TID)
Study: 37658083
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg)
Study: 37658272
Drug: NCT (Neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCT (Neoadjuvant Chemotherapy)
Study: 37658468
Drug: Allogeneic adipose-derived
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic adipose-derived mesenchymal stem cell (ASC) injection into the submandibular glands (n=60)
Study: 37658468
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (CryoStor10, n=60)
Study: 37658603
Drug: HSV-1-targeting CRISPR
Normalized name: HSV-1 G207
DrugBank: G207 (DB05827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSV-1-targeting CRISPR formulation
Study: 37659025
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (adjuvant therapy)
Study: 37659283
Drug: Prednisone 40
Normalized name: prednisone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 40 mg per day for one week
Study: 37659673
Drug: Guselkumab 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 400 mg
Study: 37659673
Drug: Guselkumab 200
Normalized name: guselkumab 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 200 mg (nonresponders at week 12)